E-resources
PDF-
Solomon, Scott D; McMurray, John J.V; Anand, Inder S; Ge, Junbo; Lam, Carolyn S.P; Maggioni, Aldo P; Martinez, Felipe; Packer, Milton; Pfeffer, Marc A; Pieske, Burkert; Redfield, Margaret M; Rouleau, Jean L; van Veldhuisen, Dirk J; Zannad, Faiez; Zile, Michael R; Desai, Akshay S; Claggett, Brian; Jhund, Pardeep S; Boytsov, Sergey A; Comin-Colet, Josep; Cleland, John; Düngen, Hans-Dirk; Goncalvesova, Eva; Katova, Tzvetana; Kerr Saraiva, Jose F; Lelonek, Małgorzata; Merkely, Bela; Senni, Michele; Shah, Sanjiv J; Zhou, Jingmin; Rizkala, Adel R; Gong, Jianjian; Shi, Victor C; Lefkowitz, Martin P
The New England journal of medicine, 10/2019, Volume: 381, Issue: 17Journal Article
Patients with heart failure with preserved ejection fraction were assigned to receive sacubitril–valsartan or valsartan. At a median of 35 months, there was no significant between-group difference in the composite outcome of total hospitalizations for heart failure or death from cardiovascular causes.
